Clinical Trial

At AACR 2026, CREATE Medicines debuts its RetroT platform, an all-RNA system for stable gene delivery that avoids viral vectors and reshapes cell therapy.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

Biopharma veteran Glenn Gormley joins Aktis's board, bringing deep ADC expertise to guide the company's next-gen radiopharmaceutical pipeline.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.

Investors eye BioCryst's May 6th report for insights into ORLADEYO's growth, a pivotal acquisition, and its strategy in the competitive rare disease market.

Scientists have created the first continent-wide map of bird flu's spread, explaining human cases and assessing the risk of a future pandemic.

Promising early safety data for a novel drug, KM-023, brings a potential first-ever targeted treatment for the devastating Olmsted syndrome a step closer.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.

MeiraGTx will present 3-year data on a one-time therapy for radiation-induced dry mouth, a condition affecting millions of head and neck cancer survivors.

The Swiss medtech firm reports a massive Q1 sales jump, backed by strong clinical data and a strategic US manufacturing expansion to meet surging demand.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

The medical device firm reports 20% Q1 revenue growth, fueled by new billing codes that boost Barostim approvals and a trial to triple its patient base.

A novel drug combination shows promising early results for a deadly ovarian cancer, potentially expanding the benefit of immunotherapy to more patients.

New data shows Imofinostat turns 'cold' colorectal tumors 'hot' for immunotherapy and breaks chemo-resistance in pancreatic cancer, fueling pivotal trials.

A new study shows the feasibility of a single device for glucose monitoring and insulin delivery, aiming to simplify life for millions with diabetes.

Backed by FDA approval and strong clinical data, EBR Systems' leadless WiSE pacer is set to transform cardiac therapy for previously untreatable patients.

A new non-invasive therapy using ultrasound to activate a cancer-targeting drug enters a crucial Phase 2b trial, offering new hope for glioblastoma patients.

With its European trial launch, Kainova's DT-7012 aims to disarm cancer's bodyguards, offering new hope for patients with advanced solid tumors.

With the hire of a top scientist, a minority-owned IT firm signals its ambition to tackle complex federal health challenges and compete with industry giants.